8X71
Crystal structure of Peroxiredoxin I in complex with compound 19-064
Summary for 8X71
Entry DOI | 10.2210/pdb8x71/pdb |
Descriptor | Peroxiredoxin-1, methyl 3-[[(2~{R},4~{a}~{S},6~{a}~{R},6~{a}~{S},14~{a}~{S},14~{b}~{R})-2,4~{a},6~{a},6~{a},9,14~{a}-hexamethyl-10-oxidanyl-11-oxidanylidene-1,3,4,5,6,13,14,14~{b}-octahydropicen-2-yl]carbamoylamino]oxetane-3-carboxylate (3 entities in total) |
Functional Keywords | oxidoreductase-inhibitor complex, oxidoreductase/inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 2 |
Total formula weight | 39831.61 |
Authors | |
Primary citation | Wang, J.,Rong, Q.,Ye, L.,Fang, B.,Zhao, Y.,Sun, Y.,Zhou, H.,Wang, D.,He, J.,Cui, Z.,Zhang, Q.,Kang, D.,Hu, L. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors. J.Med.Chem., 67:7197-7223, 2024 Cited by PubMed: 38655686DOI: 10.1021/acs.jmedchem.4c00051 PDB entries with the same primary citation |
Experimental method |
Structure validation
Download full validation report![Download](/newweb/media/icons/dl.png)
![Download](/newweb/media/icons/dl.png)